dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lakeman, Inge |
dc.contributor.author | van den Broek, Alexandra J. |
dc.contributor.author | Vos, Juliën A. M. |
dc.contributor.author | Barnes, Daniel |
dc.contributor.author | Adlard, Julian |
dc.contributor.author | andrulis, irene |
dc.contributor.author | Balmaña, Judith |
dc.date.accessioned | 2022-02-25T13:41:35Z |
dc.date.available | 2022-02-25T13:41:35Z |
dc.date.issued | 2021-09 |
dc.identifier.citation | Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, et al. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 Sep;23(9):1726–37. |
dc.identifier.issn | 1530-0366 |
dc.identifier.uri | https://hdl.handle.net/11351/7091 |
dc.description | Predicció de risc de càncer de mama; Dones europees; Variant patògena heterozigota |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Genetics in Medicine;23(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Diagnòstic |
dc.subject | Malalties congènites |
dc.subject | Diàtesi |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /diagnosis |
dc.subject.mesh | Genetic Predisposition to Disease |
dc.title | The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41436-021-01198-7 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /diagnóstico |
dc.subject.decs | predisposición genética a la enfermedad |
dc.relation.publishversion | https://doi.org/10.1038/s41436-021-01198-7 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lakeman IMM] Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. [van den Broek AJ, Vos JAM] Division of Molecular Pathology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. [Barnes DR] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Adlard J] Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK. [Andrulis IL] Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. [Balmaña J] Hereditary cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34113011 |
dc.identifier.wos | 000659837100010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |